MANNKIND CORP Amortization of Debt Discount (Premium)
MANNKIND CORP (MNKD) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-02-26
- MANNKIND CORP amortization of debt discount (premium) for the quarter ending 2025-12-31 was $0.00.
- MANNKIND CORP amortization of debt discount (premium) for the quarter ending 2025-09-30 was $0.00.
- MANNKIND CORP amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00.
- MANNKIND CORP amortization of debt discount (premium) for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP amortization of debt discount (premium) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- MANNKIND CORP amortization of debt discount (premium) for fiscal 2024 was $85.00K, a 79.91% decline from fiscal 2023.
- MANNKIND CORP amortization of debt discount (premium) for fiscal 2023 was $423.00K.
- MANNKIND CORP amortization of debt discount (premium) for fiscal 2018 was $1.16M, a 32.06% decline from fiscal 2017.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $85.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $85.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $85.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $85.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $423.00K 10-K · filed 2026-02-26 | |||
| 2019-06-30 | $69.00K 10-Q · filed 2019-08-07 | $141.00K 10-Q · filed 2019-08-07 | $224.00K derived: sum of 3 quarters · filed 2019-08-07 | $599.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | $72.00K 10-Q · filed 2019-05-07 | $155.00K derived: sum of 2 quarters · filed 2019-05-07 | $530.00K derived: sum of 3 quarters · filed 2019-05-07 | $915.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $458.00K derived: sum of 2 quarters · filed 2019-02-26 | $843.00K derived: sum of 3 quarters · filed 2019-08-07 | $1.16M 10-K · filed 2019-02-26 |
| 2018-09-30 | $375.00K 10-Q · filed 2018-11-01 | $760.00K derived: sum of 2 quarters · filed 2019-08-07 | $1.07M 10-Q · filed 2018-11-01 | $1.21M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-06-30 | $385.00K 10-Q · filed 2019-08-07 | $698.00K 10-Q · filed 2019-08-07 | $831.00K derived: sum of 3 quarters · filed 2019-08-07 | $1.26M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $310.00K 10-Q · filed 2019-05-07 | $446.00K derived: sum of 2 quarters · filed 2019-05-07 | $877.00K derived: sum of 3 quarters · filed 2019-05-07 | $1.56M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $567.00K derived: sum of 2 quarters · filed 2019-02-26 | $1.25M derived: sum of 3 quarters · filed 2019-02-26 | $1.70M 10-K · filed 2019-02-26 |
| 2017-09-30 | $431.00K 10-Q · filed 2018-11-01 | $1.12M derived: sum of 2 quarters · filed 2018-11-01 | $1.56M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $686.00K 10-Q · filed 2018-08-02 | $1.13M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $447.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $1.72M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $1.55M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |